IASO Biotherapeutics
Dr. Tan joined IASO Biotherapeutics in 2018, and is currently the company’s Vice President for Research & Development for Antibodies. Dr. Tan graduated with Ph.D. in Biochemistry and Molecular Biology from Peking University. He is an expert in development technologies for antibody drugs including construction of human antibody libraries, antibody panning, antibody bio-activity identification and antibody protein engineering, among others. He has 6 antibody patents and 4 CAR-T patents under his name.
Before joining IASO Biotherapeutics, Dr. Tan was Head of Antibody R&D Department in Eureka Therapeutics, Inc., having completed dozens of therapeutic antibody research projects, some of which have entered the clinical stage.
This person is not in any offices
IASO Biotherapeutics
IASO Biotherapeutics is a biopharmaceutical company focused on the development of cell therapies in the field of oncology.